Randomised clinical trial: rifaximin improves health‐related quality of life in cirrhotic patients with hepatic encephalopathy – a double‐blind placebo‐controlled study

• Published in: Alimentary pharmacology & therapeutics Vol. 34; no. 8; pp. 853 - 861
• Main Authors: Sanyal, A., Younossi, Z. M., Bass, N. M., Mullen, K. D., Poordad, F., Brown, R. S., Vemuru, R. P., Mazen Jamal, M., Huang, S., Merchant, K., Bortey, E., Forbes, W. P.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.10.2011; Blackwell
• Subjects: Aged; Biological and medical sciences; Canada; Digestive system; Double-Blind Method; Female; Gastroenterology. Liver. Pancreas. Abdomen; Gastrointestinal Agents - therapeutic use; Hepatic Encephalopathy - drug therapy; Hepatic Encephalopathy - physiopathology; Humans; Linear Models; Liver Cirrhosis - drug therapy; Liver Cirrhosis - physiopathology; Liver. Biliary tract. Portal circulation. Exocrine pancreas; Male; Medical sciences; Middle Aged; Other diseases. Semiology; Pharmacology. Drug treatments; Quality of Life; Rifamycins - therapeutic use; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome; United States; Canada; United States; Human; Cirrhosis; Placebo; Double blind study; Digestive diseases; Hepatic disease; Clinical trial; Antituberculous agent; Rifaximin; Antibacterial agent; Health-Related Quality of Life; Hepatic encephalopathy

Aliment Pharmacol Ther 2011; 34: 853–861 Summary Background  Hepatic encephalopathy (HE) is a brain disorder that often results from cirrhosis due to viral hepatitis, metabolic and alcohol‐related liver disease, and is characterised by cognitive, psychiatric and motor impairments. Recurrent bouts of...